Dr Reddys Laboratories Ltd

Large Cap

Healthcare Sector

reflects a positive outlook for the share price

reflects a neutral outlook for the share price

reflects a negative outlook for the share price

The analysts information is for reference only and does not\n  represents an investment recommendation.

Analyst recommendation reflect the views of analysts who follow and write research reports.

Company Information is an introduction to the company’s business that details what it sell, how it was founded, what their mission is, how they manufacture or source their products, and why they serve customers.

Dr. Reddy's Laboratories is experiencing notable trading activity, with a recent decline of 0.31%. Analysts suggest a buying opportunity if the stock dips to ₹1,340–1,345.

Dr. Reddy's Stock Shows Strength Amid Decline - 13 Jun, 2025

Nomura maintains a Buy rating on Dr. Reddy's Laboratories, setting a target price of ₹1,575. Meanwhile, eight individuals were arrested for stealing Semaglutide worth ₹2 crore from the company's warehouse, raising concerns about security and profitability beyond gRevlimid.

Dr. Reddy's Faces Theft and Growth Prospects - 12 Jun, 2025

Dr. Reddy’s Laboratories will participate in the CLSA Investor Conference on June 18, 2025, in Hyderabad. The company maintains a Buy rating with a $17.40 price target, showcasing strong financial performance and positive momentum despite market challenges.

Dr. Reddy's Engages Investors at CLSA Conference - 11 Jun, 2025

Dr Reddys Laboratories Ltd has gained 0.07% today, marking its fifth consecutive session of increases. The stock is currently trading at Rs 1321.8, reflecting an 8.24% rise over the past year.

Dr Reddys Continues Upward Trend with Fifth Gain - 09 Jun, 2025

Dr. Reddy's Laboratories is poised for growth despite the impending decline of gRevlimid sales. The company is investing in GLP-1RA generics and expanding its consumer health base through acquisitions and partnerships. While revenue growth is strong, challenges remain in regulatory approvals and competition. Long-term drivers are in place, but clarity on new investments is needed.

Dr. Reddy's Laboratories: Navigating Future Opportunities - 07 Jun, 2025

Dr Reddy’s Laboratories announced a collaboration with Alvotech to develop a Keytruda biosimilar, boosting its oncology portfolio. Shares rose 4% following this news, alongside an upgrade from HSBC. LIC also increased its stake in the company to over 8.2%. This strategic partnership is expected to enhance Dr Reddy's market position significantly.

Dr Reddy's Gains from Keytruda Biosimilar Collaboration - 05 Jun, 2025

Dr. Reddy's Laboratories is actively seeking partnerships and investment opportunities to enhance its manufacturing capabilities in the US, highlighting its strong financial position.

Dr. Reddy's Explores US Manufacturing Opportunities - 03 Jun, 2025

Dr Reddy's Laboratories faces a ₹2,396 crore tax demand and legal restrictions on selling semaglutide due to a patent infringement lawsuit by Novo Nordisk.

Dr Reddy's Faces Legal Challenges and Tax Demand - 31 May, 2025

Dr Reddy's Laboratories plans to counter the impending revenue loss from Revlimid's patent expiry in January 2026 through new launches, biosimilars, and potential M&A. The company aims for sustained double-digit sales growth and is investing heavily in its pipeline, despite analysts' concerns about offsetting the Revlimid void. The CFO remains optimistic about maintaining strong financial performance.

Dr Reddy's Strategies Amid Revlimid Patent Expiry - 30 May, 2025

On May 28, 2025, Dr Reddy's Laboratories shares rose by 0.37% to Rs 1247.80, reflecting bullish investor sentiment. The company continues to show steady financial performance.

Dr Reddy's Laboratories Shows Marginal Gains - 28 May, 2025

Dr Reddys Laboratories stock experienced a rise of 1.18% to Rs 1,238.70, while also maintaining a steady price of Rs 1,224.20. The stock's inclusion in the NIFTY 50 index highlights its importance in the market, with a bullish sentiment noted in recent analyses.

Dr Reddys Laboratories Stock Shows Positive Momentum - 21 May, 2025

Dr. Reddy's Laboratories reported a revenue increase to Rs 32,643.90 crore for FY 2025, with a net profit of Rs 5,703.50 crore. Shares rose 1.12% amid positive trading volume. The company also announced participation in upcoming investor conferences, reflecting its commitment to investor relations.

Dr. Reddy's Reports Strong Earnings and Investor Engagement - 20 May, 2025

Dr Reddy's Laboratories announced that its New York API facility received a Form 483 with two observations from the USFDA following a GMP inspection conducted from May 12-16, 2025. The company plans to address these observations within the stipulated timeline.

Dr Reddy's Receives USFDA Observations for API Facility - 17 May, 2025

Dr Reddy's Laboratories shares fell 0.67% to Rs 1228.00 with high trading volume. Despite consistent revenue and profit growth, market sentiment remains bearish.

Dr Reddy's Shares Decline Amid High Volume - 16 May, 2025

Dr. Reddy's Laboratories reported significant growth in revenue and net profit from March 2021 to March 2025, with EPS increasing notably. The company maintains a low debt-to-equity ratio, indicating financial stability.

Dr. Reddy's Laboratories Financial Performance Overview - 15 May, 2025

Price to Earnings Ratio or Price to Earnings Multiple is the ratio of the share price of a stock to its earnings per share (EPS). It provides an indication of whether a stock at its current market price is expensive or cheap.

The price/earnings-to-growth ratio, or the PEG ratio, is a metric that helps investors value a stock by taking into account a company's market price, its earnings, and its future growth prospects.

Enterprise value (EV) is the total value of a company, defined in terms of its financing. It includes both the current share price (market capitalization) and the cost to pay off debt (net debt, or debt minus cash).

Alpha measures the amount that the investment has returned in comparison to the market index or other broad benchmark that it is compared against.

Beta measures a stock's volatility, the degree to which its price fluctuates in relation to the overall stock market. In other words, it gives a sense of the stock's risk compared to that of the greater market.

Dividend yield measures the quantum of earnings by way of total dividends that investors make by investing in that company.

The debt-to-total-assets ratio shows how much of a business is owned by creditors (people it has borrowed money from) compared with how much of the company's assets are owned by shareholders.

Operating cash flow (OCF) is a measure of the amount of cash generated by a company's normal business operations. Operating cash flow indicates whether a company can generate sufficient positive cash flow to maintain and grow its operations.

This widget shows the information about the stock's peers in consideration along with the different data for those peers so that the user can compare the stock with the other similar stock and invest accordingly.

Promoter holding is the amount of share of the company that is owned by the promoters. The promoters are the company's founders, who hold a majority stake in the company's capital.

A foreign institutional investor (FII) is an investor or investment fund investing in a country outside of the one in which it is registered or headquartered.

A mutual fund is a pool of money managed by a professional Fund Manager. It is a trust that collects money from a number of investors who share a common investment objective and invests the same in equities, bonds, money market instruments, and other securities.

Retail investors execute their trades through traditional or online brokerage firms or other types of investment accounts. Retail investors purchase securities for their own personal accounts and often trade in dramatically smaller amounts as compared to institutional investors.

This widget shows the bifurcation of stocks based on the percentage of stake with the different types of shareholders.

This widget will help value the stock based on the Price to Earning ratio of the stock and compare the valuation with the industry value and other similar stocks. It even shows the timeline of the valuation of the stock and its highest and lowest valuation over time.
A Time Series data is provided which compares the historical stock PE with Industry PE over the period of 5 years.

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

Mutual Funds have increased holdings from 11.14% to 12.89% in Mar 2025 quarter

This section gives you an insight into how the Mutual Funds Holding has changed for the stock over last few quarters.

MF Holding Up

Netprofit is up for the last 3 quarters, 1.25K Cr → 1.59K Cr (in ₹), with an average increase of 11.2% per quarter

This section gives you an insight into how the profit for the company has been for the last few quarters.

Profit Spike

In the last 7 days, DRREDDY stock has moved up by 3.3%

This section gives you an insight into the price movement of the stock for the last few quarters.

Price Rise

Revenue is up for the last 5 quarters, 7.31K Cr → 9.05K Cr (in ₹), with an average increase of 5.2% per quarter

This section gives you an insight into how the revenue of the company has moved for the last few quarters.

Revenue Rich

Promoters holdings remained unchanged at 26.64% of holdings in Mar 2025 quarter

This section gives you an insight into how the Promoter Holding has changed for the stock over the last few quarters.

Promoter Holding Unchanged

Retail Investor have decreased holdings from 10.22% to 10.15% in Mar 2025 quarter

This section gives you an insight into how the Retail Investors Holding has changed for the stock over last few quarters.

Retail Holding Down

Foreign Institutions have decreased holdings from 26.85% to 25.75% in Mar 2025 quarter

This section gives you an insight into how the FII Holding has changed for the stock over last few quarters.

FII Holding Down

NIFTY PHARMA

NIFTY 50

Nifty50 Value 20

Nifty100 Quality

BSE 100

S&P BSE Largecap

S&P BSE 250 LargeMidCap

NIFTY 100

BSE 200

S&P BSE Low Volatility

Nifty 200

Nifty100 Low Volatility 30

Nifty LargeMidcap 250

S&P BSE 100 ESG

Nifty 500

BSE MFG

Nifty Healthcare

S&P BSE SENSEX 50

S&P BSE 100 LargeCap TMC

S&P BSE Dividend Stability

Nifty100 Eq Weig

BSE Healthcare

BSE 500

Parag Parikh Flexi Cap Direct Growth

ICICI Prudential Value Discovery Fund Direct Plan Growth

Nippon India Large Cap Fund - Direct Plan - Growth Plan

ICICI Prudential Balanced Advantage Fund Direct Plan Growth

ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct Growth

Dr Reddys Laboratories Ltd’s net profit jumped 21.64% since last year same period to ₹1,593.30Cr in the Q4 2024-2025. On a quarterly growth basis, Dr Reddys Laboratories Ltd has generated 12.7% jump in its net profits since last 3-months.

Name	Value	Action
MACD level (12,26)	0.52	Bearish
CCI (20)	-457.47	Bullish
RSI (14)	50.52	Neutral
Momentum (10)	-0.7	Bearish
ADI (14)	20.88	Neutral
Ultimate Oscillator (7,14,28)	73.76	Bullish

Name	Value	Action
SMA (20)	1362.9	Bearish
EMA (20)	1362.45	Bearish
VWMA (20)	1362.82	Bearish
SMA (50)	1360.52	Bullish
EMA (50)	1361.24	Bullish
SMA (200)	1359.77	Bullish
EMA (200)	1359.99	Bullish
KAMA (200)	1360.54	Bullish
DEMA (200)	1360.43	Bullish

Dr Reddys Laboratories Ltd (DRREDDY)

Summary

Overall

Oscillators

Moving Averages